Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. Ca A Cancer J Clinicians. 2022;72(6):524–541. doi: 10.3322/caac.21754
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–1936. doi: 10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with Ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–950. doi: 10.1056/NEJMoa2114663
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–475. doi: 10.1038/nature23465
   PubMed Web of Science ®Google Scholar
• Klein ME, Kovatcheva M, Davis LE, et al. CDK4/6 inhibitors: the mechanism of action May not be as simple as Once thought. Cancer Cell. 2018;34(1):9–20. doi: 10.1016/j.ccell.2018.03.023
   PubMed Web of Science ®Google Scholar
• Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): analyses from PALOMA-2. J Clin Oncol. 2022;40(17_suppl):LBA1003–LBA.
   Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi: 10.1056/NEJMoa1810527
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Rugo HS, Im S-A, et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): updated analyses from PALOMA-3. J Clin Oncol. 2021;39(15_suppl):1000–. doi: 10.1200/JCO.2021.39.15_suppl.1000
   Web of Science ®Google Scholar
• Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk Invasive HR-Positive and HER2-negative early breast cancer—the penelope-B trial. J Clin Oncol. 2021;39(14):1518–1530. doi: 10.1200/JCO.20.03639
   PubMed Web of Science ®Google Scholar
• Gnant M, Dueck AC, Frantal S, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40(3):282–293. doi: 10.1200/JCO.21.02554
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212–222. doi: 10.1016/S1470-2045(20)30642-2
   PubMed Web of Science ®Google Scholar
• IBRANCE (palbociclib) US. 2015. [Package insert].
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-Positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi: 10.1056/NEJMoa1609709
   PubMed Web of Science ®Google Scholar
• Guidelines®) NCPGiON. Breast cancer version 4.2023 — March 23, 2023. Clin Breast Cancer. 2023;23(5):A4–A6. doi: 10.1016/S1526-8209(23)00149-0
   Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2019;382(6):514–524. doi: 10.1056/NEJMoa1911149
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915. doi: 10.1016/S1470-2045(18)30292-4
   PubMed Web of Science ®Google Scholar
• Im S-A, Lu Y-S, Bardia A, et al. Overall survival with Ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316. doi: 10.1056/NEJMoa1903765
   PubMed Web of Science ®Google Scholar
• Lu YS, Im SA, Colleoni M, et al. Updated Overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–859. doi: 10.1158/1078-0432.CCR-21-3032
   PubMed Web of Science ®Google Scholar
• Slamon D, Stroyakovskiy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Chicaago (IL USA): ASCO; 2023.
   Google Scholar
• KISQALI (ribociclib), US. 2017. [package insert].
   Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi: 10.1200/JCO.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Johnston S, O’Shaughnessy J, Martin M, et al. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021;7(1):80. doi: 10.1038/s41523-021-00289-7
   PubMed Web of Science ®Google Scholar
• Goetz M, Toi M, Huober J, et al. LBA15 MONARCH 3: interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer. Ann Oncol. 2022;33:S138.
   Web of Science ®Google Scholar
• Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi: 10.1200/JCO.2017.73.7585
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on Overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–124. doi: 10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi: 10.1200/JCO.20.02514
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77–90. doi: 10.1016/S1470-2045(22)00694-5
   PubMed Web of Science ®Google Scholar
• VERZENIO (abemaciclib) US. 2017. [package insert].
   Google Scholar
• Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39. doi: 10.1186/1465-9921-13-39
   PubMed Web of Science ®Google Scholar
• Finn RS, Rugo HS, Gelmon KA, et al. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/Human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 Years of follow-up. Oncology. 2021;26(5):e749–e55. doi: 10.1002/onco.13684
   Google Scholar
• Zhang Y, Ma Z, Sun X, et al. Interstitial lung disease in patients treated with Cyclin-dependent kinase 4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Breast. 2022;62:162–169. doi: 10.1016/j.breast.2022.02.011
   PubMed Web of Science ®Google Scholar
• Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219–227. doi: 10.1007/s10549-020-06001-w
   PubMed Web of Science ®Google Scholar
• Hanania AN, Mainwaring W, Ghebre YT, et al. Radiation-induced lung injury: assessment and Management. Chest. 2019;156(1):150–162. doi: 10.1016/j.chest.2019.03.033
   PubMed Web of Science ®Google Scholar
• Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616–627. doi: 10.1016/j.annonc.2022.03.006
   PubMed Web of Science ®Google Scholar
• Beddok A, Xu HP, Henry AA, et al. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature. Br J Cancer. 2020;123(6):905–908. doi: 10.1038/s41416-020-0957-9
   PubMed Web of Science ®Google Scholar
• Yap YS, Kim S, Chiu J, et al. Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high-risk early breast cancer: monarchE. Ann Oncol. 2021;32:S41–S42. doi: 10.1016/j.annonc.2021.03.062
   Web of Science ®Google Scholar
• Funasaka C, Naito Y, Kusuhara S, et al. Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study. Jpn J Clin Oncol. 2023;53(2):105–114. doi: 10.1093/jjco/hyac168
   PubMed Web of Science ®Google Scholar
• Freites-Martinez A, Santana N, Arias-Santiago S. Using the common terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliográficas. 2021 Jan;112(1):90–92. doi: 10.1016/j.ad.2019.05.009
   PubMed Web of Science ®Google Scholar
• Distefano G, Fanzone L, Palermo M, et al. HRCT patterns of drug-induced interstitial lung diseases: a review. Diagnostics. 2020;10(4):244. doi: 10.3390/diagnostics10040244
   Web of Science ®Google Scholar
• Birnhuber A, Egemnazarov B, Biasin V, et al. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis. Respir Res. 2020;21(1):167. doi: 10.1186/s12931-020-01433-w
   PubMed Web of Science ®Google Scholar
• FDA U. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer 2019. Available from: https://www.fda.gov/media/130787/download.
   Google Scholar
• Rugo HS, Huober J, García-Sáenz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncology. 2021;26(1):e53–e65. doi: 10.1002/onco.13531
   Google Scholar
• Nijhof AVO, Wortelboer N, Noort V, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2023;41(17_suppl):LBA1000–LBA.
   Web of Science ®Google Scholar
• Eren MF, Ay Eren A, Sayan M, et al. The impact of Everolimus and radiation therapy on pulmonary fibrosis. Medicina. 2020;56(7):348. doi: 10.3390/medicina56070348
   PubMedGoogle Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. NEJM. 2012;366:520–529. doi: 10.1056/NEJMoa1109653
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Tarantino P, Tolaney SM. Detecting and managing T-DXd–related interstitial lung disease: the five “S” rules. JCO Oncol Pract. 2023;19(8): 526–527 .
   PubMedGoogle Scholar
• Kumagai K, Aida T, Tsuchiya Y, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636–4645. doi: 10.1111/cas.14686
   PubMed Web of Science ®Google Scholar